MDxHealth Reports Q3 2026 Results Impacted by Sales Turnover and ExoDx Integration
MDxHealth (MDXH) reported third-quarter 2026 revenue of $22.7 million, remaining flat year-over-year due to commercial execution disruptions caused by high sales force turnover. The company's financial performance was heavily influenced by the integration of ExoDx and the strategic wind-down of its Resolve UTI business, leading to an increased operating loss of $8.1 million. The shift in product mix toward liquid-based diagnostics significantly altered margins; gross margin fell to 61.8% from 65% previously as liquid-based testing volumes rose following the ExoDx acquisition. While tissue-based test volumes declined by 11%, liquid-based volumes saw substantial growth. Management cautioned that recovery may be gradual, noting that new sales representatives typically require one to two quarters to reach full productivity.
Topics: acquisition integration EBITDA gross profit net loss operating loss revenue